Efficacy and Safety of Atorvastatin in the Treatment Between Young-Elderly and Old-Elderly Patients with Dyslipidemia

ObjectiveTo explore the Young-elderly and Old-elderly patients to apply the efficacy and safety of Atorvastatin.MethodsAll the 88 hyperlipidemia participants who never used statin were divided into two groups, the young-elderly (65-75 years) and old-elderly (76-85 years). All patients were initiated on 10 mg atorvastatin daily, and reviewed low-density lipoprotein cholesterol (LDL-C) every 4 weeks. The dose should be doubled if it was ineffective in reducing LDL-C to the target levels, but not more than 40 mg daily. During 12 weeks of treatment, blood lipids and other biochemical parameters were tested before treatment and after 4 weeks, 8 weeks,12 weeks of treatment.Results (1)Atorvastatin average dose achieving 18.5 mg at 12 weeks. Compared with that before treatment, LDL-C levels of all Old-elderly was reduced by 36.3% (P<0.01). LDL-C levels of Old-elderly patients was marginally higher than Young-elderly group, 37.8% and 34.4%, respectively. LDL-C levels achieved target level at week 12 for 78.7%. Compliance of Old-elderly patients was higher than Young-elderly group, 82.9% and 73.5%, respectively.(2) Compared with baseline, the growth of alanine aminotransferase (ALT) levels were comparable between the two groups, achieved the highest at 12 weeks, which is not more than 3 times the upper limit of normal. Creatine kinase (CK) levels had no significant change. Conclusions Recommended dose of Atorvastatin could effectually reduce LDL-C levels of elderly patients.The reduction and compliance of LDL-C with Atorvastatin in Old-elderly patients is higher than that in the Young-elderly patients, and the security is identical between the two groups.Elderly patients should be monitored with liver enzymes.